CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
Standard
CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. / Maecker, Britta; Jack, Thomas; Zimmermann, Martin; Abdul-Khaliq, Hashim; Burdelski, Martin; Fuchs, Alexandra; Hoyer, Peter; Koepf, Sabine; Kraemer, Ulrike; Laube, Guido F; Müller-Wiefel, Dirk E.; Netz, Heinrich; Pohl, Martin; Toenshoff, Burkhard; Wagner, Hans-Joachim; Wallot, Michael; Welte, Karl; Melter, Michael; Offner, Gisela; Klein, Christoph.
in: J CLIN ONCOL, Jahrgang 25, Nr. 31, 31, 2007, S. 4902-4908.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
AU - Maecker, Britta
AU - Jack, Thomas
AU - Zimmermann, Martin
AU - Abdul-Khaliq, Hashim
AU - Burdelski, Martin
AU - Fuchs, Alexandra
AU - Hoyer, Peter
AU - Koepf, Sabine
AU - Kraemer, Ulrike
AU - Laube, Guido F
AU - Müller-Wiefel, Dirk E.
AU - Netz, Heinrich
AU - Pohl, Martin
AU - Toenshoff, Burkhard
AU - Wagner, Hans-Joachim
AU - Wallot, Michael
AU - Welte, Karl
AU - Melter, Michael
AU - Offner, Gisela
AU - Klein, Christoph
PY - 2007
Y1 - 2007
N2 - PURPOSE: To identify prognostic factors of survival in pediatric post-transplantation lymphoproliferative disorder (PTLD) after solid organ transplantation. PATIENTS AND METHODS: A multicenter, retrospective case analysis of 55 pediatric solid organ graft recipients (kidney, liver, heart/lung) developing PTLD were reported to the German Pediatric-PTLD registry. Patient charts were analyzed for tumor characteristics (histology, immunophenotypes, cytogenetics, Epstein-Barr virus [EBV] detection), stage, treatment, and outcome. Probability of overall and event-free survival was analyzed in defined subgroups using univariate and Cox regression analyses. RESULTS: PTLD was diagnosed at a median time of 29 months after organ transplantation, with a significantly shorter lag time in liver (0.83 years) versus heart or renal graft recipients (3.33 and 3.10 years, respectively; P = .001). The 5-year overall and event-free survival was 68% and 59%, respectively, with 59% of patients surviving 10 years. Stage IV disease with bone marrow and/or CNS involvement was associated independently with poor survival (P = .0005). No differences in outcome were observed between early- and late-onset PTLD, monomorphic or polymorphic PTLD, and EBV-positive or EBV-negative PTLD, respectively. Patients with Burkitt or Burkitt-like PTLD and c-myc translocations had short survival (<1 year). CONCLUSION: Stage IV disease is an independent risk factor for poor survival in pediatric PTLD patients. Prospective multicenter trials are needed to delineate additional risk factors and to assess treatment approaches for pediatric PTLD.
AB - PURPOSE: To identify prognostic factors of survival in pediatric post-transplantation lymphoproliferative disorder (PTLD) after solid organ transplantation. PATIENTS AND METHODS: A multicenter, retrospective case analysis of 55 pediatric solid organ graft recipients (kidney, liver, heart/lung) developing PTLD were reported to the German Pediatric-PTLD registry. Patient charts were analyzed for tumor characteristics (histology, immunophenotypes, cytogenetics, Epstein-Barr virus [EBV] detection), stage, treatment, and outcome. Probability of overall and event-free survival was analyzed in defined subgroups using univariate and Cox regression analyses. RESULTS: PTLD was diagnosed at a median time of 29 months after organ transplantation, with a significantly shorter lag time in liver (0.83 years) versus heart or renal graft recipients (3.33 and 3.10 years, respectively; P = .001). The 5-year overall and event-free survival was 68% and 59%, respectively, with 59% of patients surviving 10 years. Stage IV disease with bone marrow and/or CNS involvement was associated independently with poor survival (P = .0005). No differences in outcome were observed between early- and late-onset PTLD, monomorphic or polymorphic PTLD, and EBV-positive or EBV-negative PTLD, respectively. Patients with Burkitt or Burkitt-like PTLD and c-myc translocations had short survival (<1 year). CONCLUSION: Stage IV disease is an independent risk factor for poor survival in pediatric PTLD patients. Prospective multicenter trials are needed to delineate additional risk factors and to assess treatment approaches for pediatric PTLD.
M3 - SCORING: Zeitschriftenaufsatz
VL - 25
SP - 4902
EP - 4908
JO - J CLIN ONCOL
JF - J CLIN ONCOL
SN - 0732-183X
IS - 31
M1 - 31
ER -
